 
About the Program
Program Overview
Chronic HCV (CHC) is a common viral infection that afflicts millions of people in the United States. It is a significant public health issue, because CHC can evolve into states that are associated with chronic inflammation, progressive fibrosis, cirrhosis, and malignancy. In recent years, significant progress has been made in the treatment of CHC, but many clinicians who manage patients infected with HCV are not aware of the full range of complex and emerging treatment options available or how to apply them to various patient scenarios. Due to the rapidly changing landscape in CHC management, this situation can significantly affect the treatment of patients with HCV infection and the quality of the care they receive, potentially affecting patient outcomes, increasing morbidity, mortality, and treatment costs.
The HCV Virtual Patient program is an interactive, case-based program featuring real-world case scenarios discussed by HCV thought leaders. Participants will be asked to assess and treat a variety of HCV-infected patient types with the direction and consultation of HCV thought leaders. This program provides important information that can be directly applied to clinical practice, thereby increasing the delivery of optimal care to patients with HCV infection in the United States.
Target Audience
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.
Learning Objectives
After completing this activity, participants should be better able to:
- Explain the long-term consequences of untreated CHC
- Implement individualized antiviral treatment based on patient characteristics using available treatment options for patients with CHC
- Develop optimal approaches for managing adverse events to facilitate adherence in patients being treated for CHC
- Manage drug-drug interactions and other treatment issues experienced by patients with CHC patients and patients with HCV/HIV co-infection
Release Date: June 22, 2016
Expiration Date: June 22, 2017
Estimated time to complete each Virtual Patient Case: 30-60 minutes
Media: Internet
Faculty
Brenda Appolo PA-C, MHS
Hepatology Physician Assistant
Physician Assistant /
Nurse Practitioner Manager
Division of Gastroenterology
University of Pennsylvania
Philadelphia, Pennsylvania
|
Nezam H. Afdhal, MD
Professor of Medicine,
Harvard School of Medicine
Chief of Hepatology,
Director of Liver Center
Beth Israel Deaconess
Medical Center
Boston, Massachusetts
|
David E. Bernstein, MD, FACG
Chief
Division of Hepatology and
Center for Liver Diseases
North Shore Long Island
Jewish Health Care System
Professor of Medicine
Hofstra North Shore-LIJ
School of Medicine
New York, New York
|
Douglas T. Dieterich, MD
Professor of Medicine and
Director of CME,
Department of Medicine
Director of Outpatient Hepatology
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York
|
Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
|
Lennox Jeffers, MD
Chief of Hepatology
Miami VA Medical Center
Associate Chief
Center for Liver Disease,
Professor of Medicine
University of Miami’s
School of Medicine
Miami, Florida
|
Paul Kwo, MD
Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana
|
Alain H. Litwin, MD, MPH
Professor of Medicine
Professor of Clinical Psychiatry
& Behavioral Sciences
Albert Einstein College of Medicine
Montefior Medical Center
Bronx, New York
|
K. Rajender Reddy, MD
Ruimy Family President's Distinguished Professor of Medicine
Professor of Medicine in Surgery
Director of Hepatology
Director, Viral Hepatitis Center
University of Pennsylvania
Philadelphia, Pennsylvania
|
Mark Sulkowski, MD
Professor of Medicine and
Medical Director
Viral Hepatitis Center
Johns Hopkins University
School of Medicine
Baltimore, Maryland |
Stacey B. Trooskin, MD, PhD
Assistant Professor
Division of Infectious Diseases
and HIV Medicine
Drexel University College of Medicine
Philadelphia, Pennsylvania |
|
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation (Case 2)
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation (Cases 1, 3, 4)
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Credit Designation (Cases 5, 6, 7, 8, 9, 10)
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners
with high quality CME activities and related materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of a commercial interest.
The faculty reported the following financial
relationships or relationships to products or devices they or their
spouse/life partner have with commercial interests related to the
content of these CME activities:
Brenda Appolo PA-C, MHS
- Consulting Fees: BMS, Merck, Gilead
- Fees for Non-CME/CE Services Received Directly from a Commercial
Interest or thier Agents (e.g., speakers' bureaus: BMS, Merck, Gilead
Nezam Afdhal, MD
- Consulting Fees: Merck, Gilead, Echosens, GSK, Ligand, Janssen, Roivant, Co-Crystal, Shionogi
- Research Support: Gilead, Abbvie, BMS
- Employee/Salary: Spring Bank Pharmaceuticals
- Other: Director-TRIO Healthcare
- Stock: Allurion, Gilead, Spring Bank Pharmaceuticals
David E. Bernstein, MD, FACG
- Consulting Fees: Abbvie, Gilead, Merck
- Fees for Non-CME/CE Services Received Directly from a Commercial
Interest or thier Agents (e.g., speakers' bureaus: Abbvie, BMS, Gilead,
Merck
- Contracted Research: Abbvie, BMS, Gilead, Merck
Douglas Dieterich, MD
- Consulting Fees: Gilead, BMS, AbbVie, Janssen
- Fees for Non-CME/CE Services Received Directly from a Commercial
Interest or thier Agents (e.g., speakers' bureaus: Gilead, BMS, AbbVie,
Janssen
- Contracted Research: Gilead, BMS, AbbVie, Janssen
Ian Frank, MD
- Consulting Fees: Gilead
- Contracted Research (to UPenn): ViiV, GSK
Paul Kwo, MD
- Consulting Fees: Abbott, Abbvie, Quest, CVS, BMS, Gilead, Janssen, Merck, Alnylam
- Contracted Research: Abbvie, BMS, Gilead, Janssen, Merck, Contanus, ESAI
- Other (DSMB): Inovio
Lennox Jeffers, MD
Alain H. Litwin, MD, MPH
- Consulting Fees: Gilead, Merck, Abbvie, BMS, Janssen
- Contracted Research: Gilead, Merck
K. Rajender Reddy, MD
- Consulting Fees: BMS, Gilead, Abbvie, Janssen, Merck
- Contracted Research (To UPenn): BMS, Gilead, Abbvie, Janssen, Merck
Mark Sulkowski, MD
- Contracted Research (to JHU): Abbvie, Gilead, Janssen, Merck
- Consulting Fees: Abbvie, Co-Crystal, Gilead, Janssen, Merck, Trek
Stacey B. Trooskin, MD, PhD
Consulting Fees: Gilead
Contracted Research: Gilead
The planners and managers reported the following financial
relationships or relationships to products or devices they or their
spouse/life partner have with commercial interests related to the
content of these CME activities:
The following PIM planner and managers:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison,
PharmD; Samantha Mattiucci, PharmD, CHCP; Jan Shultz, RN, MSN, CHCP
and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their
spouse/life partner do not have any financial relationships or
relationships to products or devices with any commercial interests
related to the content of this CME/CE activity of any amount during the past 12 months.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period, June 22, 2016 through June 22, 2107, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 11398. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs
|
